#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

COSYREL –  a drug for patients with coronary artery disease and heart failure


Authors: J. Špinar 1;  J. Vítovec 2
Authors‘ workplace: Interní kardiologická klinika LF MU a FN Brno, Brno 1;  I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně 2
Published in: Kardiol Rev Int Med 2017, 19(1): 62-67

Overview

Fixed combinations increase the adherence/ compliance of patients to treatment and so increase the disease control. 5 basic drug groups are recommended for the treatment of hypertension and the main role plays the RAAS blockade, especially ACE inhibitors. These are combined with calcium channel blockade dihydropyridines or metabolically neutral indapamid especially in patients with metabolic syndrome. The combination with betablockers is recommended in patients with ischemic heart disease. Cosyrel is the first fixed combination of betablockers (bisoprolol fumarate) and ACE inhibitor (perindopril arginin) available on Czech market. The drug is indicated in patients with ischemic heart disease, hypertension and/ or heart failure (doses 5 mg bisoprolol/ 5 mg perindopril, 10 mg bisoprolol/ 5 mg perindopril). The combination of perindopril + betablockers decreases the primary endpoint (cardiovascular mortality, nonfatal MI a resuscitation) by 24%, fatal and nonfatal MI by 28%, hospitalisation for heart failure by 45% and all-cause mortality by 13% in the EUROPA trial.

Keywords:
hypertension –  heart failure –  perindopril –  bisoprolol


Sources

1. Bussien JP, d’Amore TF, Perret L et al. Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects. Clin Pharmacol Ther 1986; 39(5): 554– 558.

2. Hui Y, Dai Z, Chen X et al. Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension. Chin Med J Engl 1995; 108(9): 678– 681.

3. Agabiti-Rosei E, Ambrosioni E, Finardi G et al. Perindopril versus captopril: efficacy and acceptability in an Italian multicenter trial. Am J Med 1992; 92(2): 79S– 83S.

4. Grandi AM, Bignotti M, Gaudio G et al. Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: perindopril versus isradipine. J Cardiovasc Pharmacol 1995; 26(5): 737– 741.

5. 2013 ESH/ ESC guidelines for the management of arterial hypertension. J Hypertens 2013; 31(7): 1281– 1357. doi: 10.1097/ 01.hjh.0000431740.32696.cc.

6. Filipovský J, Widimský J jr, Ceral J et al. Dia­gnostické a léčebné postupy u arteriální hypertenze –  verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58(10): 785– 802.

7. Mancia G, Laurent S, Agabiti-Rosei E et al. Reap­praisal of European guidelines on hypertension man­agement: a European Society of Hypertension Task Force document. J Hypertens 2009; 27(11): 2121– 2158. doi: 10.1097/ HJH.0b013e328333146d.

8. Špinar J, Souček M. Přehodnocení doporučení pro dia­gnostiku a léčbu hypertenze. Vnitř Lék 2010; 56(2): 157– 161.

9. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pres­sure: meta-analysis on 11,000 participants from 42 trials. Am J Medicine 2009; 122(3): 290– 300. doi: 10.1016/ j.amjmed.2008.09.038.

10. Kaplan NM. Beta-blockers in hypertension adding insult to injury. J Am Coll Cardiol 2008; 52(18): 1490– 1491. doi: 10.1016/ j.jacc.2008.08.008.

11. Vítovec J, Špinar J. Diuretika a betablokátory v léčbě hypertenze. Int Med Praxi 2012; 14(12): 458– 460.

12. Špinar J, Vítovec J. Betablokátory. Acta Medicinae 2016; 6: 10– 17.

13. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; doi: 10.1093/  eurheartj/ ehw106.

14. The Task Force for the dia­gnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): 2016 ESC Guidelines for the dia­gnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37(29): 2315– 2381. doi: 10.1093/ eurheartj/ ehw128.

15. Vítovec J, Špinar J. Betapres –  nová fixní kombinace pro preventivní kardiologii. Hypertenze a kardiovaskulární prevence 2014; 3(1): 30– 32.

16. Vítovec J, Špinar J. Beta-blockers in the treatment of chronic heart failure. How should results of clinical studies be introduced into clinical practice. Vnitř Lék 2000; 46: 161– 165.

17. Špinar J, Hradec J, Špinarová L et al. Summary of the 2016 ESC Guidelines on the dia­gnosis and treatment of acute and chronic heart failure. Prepared by the Czech Society of Cardiology. Cor Vasa 2016; 58(5): 597– 636. doi: 10.1016/ j.crvasa.2016.09.004.

18. Špinar J. Komentář k doporučeným postupům ESC/ ČKS Farmakoterapie srdečního selhání. Kardiol Rev Int Med 2016; 18(4): 234– 239.

19. Lábr K, Špinar J, Pařenica J et al. Betablokátory v registru chronického srdečního selhání FAR NHL. Kardiol Rev Int Med 2017; 19(1): 68–72.

20. Kolandaivelu K, Leiden BB, O’Gara PT et al. Non-adherence k užívání medikace pro léčbu kardiovaskulárních onemocnění Eur Heart J 2014; 35(46): 3267– 3276. doi: 10.1093/ eurheartj/ ehu364.

21. Ho PM, Magid DJ, Shetterly SM et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery dinase. Am Heart J 2008; 155(4): 772– 779. doi: 10.1016/ j.ahj.2007.12.011.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#